Perfuze said today that it raised more than $3 million for the Millipede catheter it’s developing to treat ischemic stroke.
Although not quite in stealth mode, the Galway, Ireland-based firm is close-mouthed about its technology. CEO Wayne Allen and CTO Liam Mullins (who co-founded Embo Medical before its in 2015, $YY acquisition by C.R. Bard in 2015) founded Perfuze last year.
The €3 million ($3.4 million) seed round, earmarked for Millipede development, was led by European VC shop Earlybird. MedFocus, Enterprise Ireland and an Irish syndicate of medtech veterans and stroke physicians also participated, Perfuze said.
“We are delighted to have completed our seed-round financing with such reputable investors and look forward to working together to accelerate the growth and value of Perfuze,” Allen said in prepared remarks.
“Perfuze has a technology with the potential to significantly improve outcomes for stroke patients,” added Earlybird partner John Yianni. “We are delighted to offer our financial and commercial support in helping this exciting company grow and get its life-saving technology to market.”
($1 = €0.876001)